SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity

SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia.

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection

Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening

New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall

SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.

SECAUCUS, N.J., March 19, 2025 /PRNewswire/ -- At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss the company's strategies to drive sustainable growth and deliver long-term shareholder value.   

SUNNYVALE, Calif. and SECAUCUS, N.J., March 18, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and personalize the experiences Quest delivers to patients, providers and other customers.

To do so, Quest Diagnostics will use Google Cloud's data analytics and generative AI (gen AI) technologies, including Google Agentspace, a platform that uses gen AI to connect employees and customers with enterprise-wide knowledge and automate complex tasks through intelligent, customizable agents. The collaboration is one of the first by a national laboratory provider to use these technologies across a range of operations and administrative areas like R&D, customer experience and operations—with data privacy and security safeguards implemented.

SECAUCUS, N.J., Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange. 

During the event, Jim Davis, Chairman, CEO and President, Sam Samad, Executive Vice President and CFO, and other senior executives will provide updated views of the U.S. laboratory market, and the company's business strategy, capital deployment priorities, and its long-term outlook. Advance registration is required.

SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.

The selection is based on nine key attributes related to corporate reputation, including quality of products and services, innovation, community responsibility, social responsibility, and talent management.

Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team

SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L. Brott, an accomplished quality and regulatory affairs healthcare leader, has been named senior vice president and chief quality and regulatory affairs officer.

SECAUCUS, N.J., Jan. 2, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.